Emerging biotech companies are a significant and burgeoning sector of the pharmaceutical development market. These companies may require unique and specialized expertise to guide them through asset development. There are a multitude of considerations when evaluating an asset for development, including the vision for the asset, development and continuum capabilities, and global versus local development.
Download our latest whitepaper to learn:
- How to navigate the complexities of asset development
- Overall considerations emerging biotech companies can be discussing with development partners
- What makes a successful partner who can assist a small biotech company with necessary development strategies
This is the first in a series of white papers that will help outline considerations for asset development. Lead the pack in all steps of the development process with this guide.
Building Long-Lasting Partnerships – A Biotech Success Story
PRA has experience partnering with small biotech firms, and we understand that they require a different approach than larger pharmaceutical…
Solutions for Biotech
Biotech is in our DNA. PRA has recognized the importance of emerging biopharma since our humble beginnings, when we first started partnering with…
5 Questions Small Biotech Should Ask Their Rare Disease Development Partner
Rare disease is a complicated but rewarding space for drug developers of all sizes. Most rare diseases have no approved treatment options, making…